# A New Mode of Action of Anti-TNF, Reverse Signaling, in Rheumatoid Arthritis

> **NCT03216928** · NA · COMPLETED · sponsor: **University Hospital, Toulouse** · enrollment: 33 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DIAGNOSTIC_TEST:** Blood test

## Key facts

- **NCT ID:** NCT03216928
- **Lead sponsor:** University Hospital, Toulouse
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2020-03-12
- **Final completion:** 2020-03-12
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03216928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03216928, "A New Mode of Action of Anti-TNF, Reverse Signaling, in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03216928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*